Pipeline — registered trials by phase
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No registered trials in this stage.
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where IDEXX is lead sponsor; 0 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 10-Q2026-08-04Quarterly report
- 8-K2026-08-04Current report (material event)
- SD2026-06-01SD
- 8-K2026-05-15Current report (material event)
- 10-Q2026-05-05Quarterly report
- 8-K2026-05-05Current report (material event)
- SCHEDULE 13G2026-04-30SCHEDULE 13G
- ARS2026-03-27Annual report to holders
- DEFA14A2026-03-27DEFA14A
- DEF 14A2026-03-27Proxy statement
- SCHEDULE 13G/A2026-03-27SCHEDULE 13G/A
- 8-K2026-03-26Current report (material event)
- PRE 14A2026-03-13PRE 14A
- 10-K2026-02-20Annual report
- 8-K2026-02-13Current report (material event)
- 8-K2026-02-02Current report (material event)
- 8-K2026-01-13Current report (material event)
- 8-K2025-11-13Current report (material event)
- 10-Q2025-11-03Quarterly report
- 8-K2025-11-03Current report (material event)
- 8-K2025-10-07Current report (material event)
- 10-Q2025-08-04Quarterly report
- 8-K2025-08-04Current report (material event)
- 8-K2025-07-10Current report (material event)
- UPLOAD2025-07-07UPLOAD
- CORRESP2025-06-02CORRESP
- SD2025-05-30SD
- UPLOAD2025-05-21UPLOAD
- 8-K2025-05-09Current report (material event)
- 10-Q2025-05-01Quarterly report
- 8-K2025-05-01Current report (material event)
- CORRESP2025-04-30CORRESP
- UPLOAD2025-04-24UPLOAD
- SCHEDULE 13G/A2025-04-17SCHEDULE 13G/A
- ARS2025-03-28Annual report to holders
- DEFA14A2025-03-28DEFA14A
- DEF 14A2025-03-28Proxy statement
- PRE 14A2025-03-14PRE 14A
- 10-K2025-02-21Annual report
- 8-K2025-02-14Current report (material event)
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.